Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (07) : 698-702     DOI: 10.3971/j.issn.1000-8578.2022.21.1340
|
Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Download: PDF(7500 KB)   ( 28 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To evaluate the efficacy and safety of tislelizumab combined with chemotherapy in the treatment of urothelial carcinoma in the real word. Methods We enrolled 32 patients with urothelial carcinoma who were treated with tislelizumab and chemotherapy (gemcitabine/cisplatin or paclitaxel). The incidence of treatment-related adverse reactions during treatment and the efficacy evaluation were statistically analyzed. Results All patients were divided into two groups: 15 patients in the tislelizumab combined with paclitaxel group and 17 patients in the tislelizumab combined with GC group. Among 24 efficacy-evaluable patients, the ORR was 54.2% and the DCR was 83.3%. The ORR were 50.0% and 58.3%, and the DCR were 75.0% and 91.7% in the tislelizumab combined with paclitaxel group and the tislelizumab combined with GC group respectively. Common treatment-related adverse reactions included anemia (56.3%), loss of appetite (53.1%) and skin pruritus (50.0%). The grade 3-4 treatment-related adverse events occurred in 21.8% of patients. Common immune-related adverse reactions included skin toxicity (53.1%) and immune colitis (9.4%). Conclusion Tislelizumab combined with chemotherapy on urothelial cancer has significant curative effect, safety and controllability, but attention should be paid to immune-related adverse reactions.
Keywords Tislelizumab      Chemotherapy      Urothelial cancer      Efficacy      Adverse reaction     
ZTFLH:  R737.1  
Issue Date: 14 July 2022
 Cite this article:   
WEI Zongjie,KUANG Youlin,CHEN Yong, et al. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1340
http://www.zlfzyj.com/EN/Y2022/V49/I07/698
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
WEI Zongjie
KUANG Youlin
CHEN Yong
WANG Lu
CHEN Xiao
GOU Xin
[1] Siegeal RL, Miller KD, Fuchs HE, et al. Cancer statistis, 2022[J].
CA Cancer J Clin, 2022, 72(1): 7-33.
[2] Bellmunt J, De Wit R, Vaughn DJ, et al. Pembrolizumab as
Second-Line Therapy for Advanced Urothelial Carcinoma[J]. N
Engl J Med, 2017, 376(11): 1015-1026.
[3] Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in
metastatic urothelial carcinoma after platinum therapy (CheckMate
275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol,
2017, 18(3): 312-322.
[4] Flaig TW, Spiess PE, Agarwal N, et al. Bladder Cancer, Version
3.2020, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl
Compr Canc Netw, 2020, 18(3): 329-354.
[5] Ye D, Liu J, Zhou A, et al. Tislelizumab in Asian patients with
previously treated locally advanced or metastatic urothelial
carcinoma[J]. Cancer Sci, 2020, 112(1): 305-313.
[6] Wang Z, Zhao J, Ma Z, et al. A Phase 2 Study of Tislelizumab
in Combination With Platinum-Based Chemotherapy as Firstline
Treatment for Advanced Lung Cancer in Chinese Patients[J].
Lung Cancer, 2020, 147: 259-268.
[7] Galsky MD, Arija JáA, Bamias A, et al. Atezolizumab with
or without chemotherapy in metastatic urothelial cancer
(IMvigor130): a multicentre, randomised, placebo-controlled
phase 3 trial[J]. Lancet, 2020, 395(10236): 1547-1557.
[8] Powles T, Cs?szi T, ?zgüro?lu M, et al. Pembrolizumab alone or
combined with chemotherapy versus chemotherapy as first-line
therapy for advanced urothelial carcinoma (KEYNOTE-361):
a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021,
22(7): 931-945.
[9] Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response
by combining immune checkpoint inhibitors with chemotherapy
in solid tumors[J]. Ann Oncol, 2019, 30(2): 219-235.
[10] Von Der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine
and cisplatin versus methotrexate, vinblastine, doxorubicin, and
cisplatin in advanced or metastatic bladder cancer: results of a
large, randomized, multinational, multicenter, phase Ⅲ study[J]. J
Clin Oncol, 2000, 18(17): 3068-3077.
[11] Calabrò F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel
every 2 weeks in patients with previously untreated urothelial
carcinoma[J]. Cancer, 2009, 115(12): 2652-2659.
[12] Vaughn DJ, Broome CM, Hussain M, et al. Phase Ⅱ trial of
weekly paclitaxel in patients with previously treated advanced
urothelial cancer[J]. J Clin Oncol, 2002, 20(4): 937-940.
[13] Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albuminbound
paclitaxel for second-line treatment of metastatic urothelial
carcinoma: a single group, multicentre, phase 2 study[J]. Lancet
Oncol, 2013, 14(8): 769-776.
[14] Li L, Li G, Rao B, et al. Landscape of immune checkpoint
inhibitor-related adverse events in Chinese population[J]. Sci Rep,
2020, 10(1): 15567.
Related articles from Frontiers Journals
[1] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[2] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[3] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[4] XIE Zhanghong, HUA Qingquan. Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 282-287.
[5] FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei. Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 205-212.
[6] HOU Jiyuan, QI Peihong, WANG Haixia, GONG Zhe, SHAN Guoyong. Efficacy and Safety of Apatinib Monotherapy as Subsequent-line Therapy on Patients with Advanced Esophageal Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 219-224.
[7] LI Zuxi, HUANG Xianbin, MA Yuntao, ZHAN Weipeng, HU Ming, TIAN Hongwei, YANG Jing, . Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 225-229.
[8] LIU Zhenghao, YANG Chunguang, HU Zhiquan. Research Progress on Immunoregulation of Chemotherapeutic Agents[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 72-77.
[9] LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077.
[10] HU Lanping, QIU Dasheng. Current Status of Imaging Assessment of Cancer Response to Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1118-1122.
[11] KE Ping, JIANG Bo, HE Wenjie, TU Changling, NIE Jun, ZHU Ying, YIN Qing, SUN Ruizhu. Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1006-1011.
[12] SUN Chongyuan, ZHAO Dongbing. Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1046-1052.
[13] ?WU Zhaoyang, WANG Shenglin, SHEN Rongkai, CHEN Fei, LIN Jianhua, ZHU Xia, ZHANG Zhenzhen. Association Between Osteogenic Differentiation in Soft Tissue Lump and Clinicopathological Characteristics of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 859-863.
[14] HE Puyi, LI Xuemei, WANG Yunpeng, XU Bo, WANG Haiyun, ZHANG Jing, PU Weigao, CHEN Hao. Advances in Application of PDT Combined with Multiple Therapies on Unresectable Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 893-897.
[15] LI Yuting, DING Junli, WANG Huiyu, XU Junying. Research Progress of Immunoscore in Prediction of Tumor Prognosis and Efficacy to Treatment[J]. Cancer Research on Prevention and Treatment, 2021, 48(08): 809-813.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed